Clinical study identifies combination of 11 proteins that can predict long-term disability in patients with multiple sclerosis.
A recent study discovered a combination of 11 proteins that can predict long-term disability in patients with multiple sclerosis (MS). The study, conducted by researchers from Linköping University, the Karolinska Institute, and the University of Skövde, was recently published in the journal Nature Communications.1
As one of the most widespread neurological conditions in young adults,2 MS causes the immune system to attack the patient’s own body, targeting a fatty compound called myelin. This damages the compound leading to interference in nerve signal transmission.1
According to recent findings from the National MS Society, there are an estimated 1 million people in the United States living with MS, which is double the last reported number in 1975.2
"I think we've come one step closer to an analysis tool for selecting which patients would need more effective treatment in an early stage of the disease. But such a treatment may have side effects and be relatively expensive, and some patients don't need it," said study lead Mika Gustafsson, professor of bioinformatics at the Department of Physics, Chemistry, and Biology at Linköping University, in the press release.
As noted in the press release, researchers analyzed nearly 1,500 proteins in samples from 92 people with suspected MS. The data were combined with information from the patients’ journals, such results of MRI scans and treatment history. Then, using machine learning, the researchers identified proteins that could predict disease progression.
Of the 11, a specific protein that was found leaking from damaged nerves can serve as a reliable biomarker for disease activity in the short term.
This study is also the first to measure a large amount of proteins utilizing proximity extension assay, combined with next-generation sequencing.
"Having a panel consisting of only 11 proteins makes it easy should anyone want to develop analysis for this. It won't be as costly as measuring 1,500 proteins, so we've really narrowed it down to make it useful for others wanting to take this further," said Sara Hojjati, doctoral student at the Department of Biomedical and Clinical Sciences at Linköping University, in the release.
Zerlasiran Achieves Significant Sustained Reduction in Lipoprotein(a) Levels with Infrequent Dosing
November 20th 2024Zerlasiran, a novel siRNA therapy, demonstrated over 80% sustained reductions in lipoprotein(a) levels with infrequent dosing in the Phase II ALPACAR-360 trial, highlighting its potential as a safe and effective treatment for patients at high risk of cardiovascular disease.
Tirzepatide Reduces Heart Failure Risk, Improves Physical Function in HFpEF Patients
November 18th 2024The Phase III SUMMIT trial showed that tirzepatide significantly reduces the risk of worsening heart failure events or death from cardiovascular causes, enhances physical function, and leads to weight loss and reduced inflammation in patients with heart failure with preserved ejection fraction.
Twice-Yearly Lenacapavir Injections Significantly Reduce HIV Risk, PURPOSE 2 Trial Shows
November 13th 2024Full Phase III PURPOSE 2 trial results suggest that twice-yearly lenacapavir could revolutionize HIV prevention by offering a convenient and effective long-acting option for individuals at risk of infection.